Sarepta Therapeutics, Inc., a developer of innovative RNA-based
therapeutics, and Flagship Biosciences LLC, a leading
tissue-based companion diagnostics firm, today announced a multi-year,
multi-product partnership for the development of automated quantitative
endpoint measurements in muscular dystrophy to support the advancement
of Sarepta’s Duchenne muscular dystrophy (DMD) drug pipeline, including
its lead candidate, eteplirsen.
for Sarepta Enters into Partnership with Flagship Biosciences to Digitally Automate the Measurement of Dystrophin, a Key Therapeutic Efficacy Marker for Muscular Dystrophy investment picks